| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | 0.034 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |